Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital AB in connection with its investment in Greenfood
Mandate

Vinge has advised Fidelio Capital AB in connection with its investment in Greenfood

August 11, 2025 M&A Employment and Benefits Trade Compliance Real Estate and Construction Commercial Agreements IT, Telecommunications and Outsourcing Financial Regulatory Intellectual Property EU, Competition and Regulatory Environmental Law Market surveillance

Vinge has advised Fidelio Capital AB in connection with its majority investment in Greenfood.

Fidelio, which has been a long-standing minority shareholder for almost 15 years is increasing its ownership in Greenfood by acquiring Nordic Capital’s stake in the group and becoming the majority owner of Greenfood.

Vinge’s team consisted of among others Jonas Bergström, Johanna Wiberg, Amanda Steen, Edvard Gustafson, Lovisa Jonassen and Anna Neubüser (M&A), Alice Göransson and Louisa Fagarasan (Employment), Hayaat Ibrahim (Compliance), Hanna Kövamees and Wilma Hellman (Real Estate), Mario Saad and Gabriel Pålsson (Commercial Agreements), Nicklas Thorgerzon, Filippa Eriksson and Sara Link (IT), Albert Wållgren, Felix Möller, Nour Makie and Gabriel Chabo (Financial Arrangements), Melinda Oldenburg, Maja Helm and Vilma Simonius (IP), Martin Johansson and Filippa Berggren (State Aid), Stina Larsson (Environment and Permits), Sebastian Örndahl, Noelia Martinez, Hilda Ivarson, Hampus Peterson and Lovisa Arpi (Merger Control) and Ellinore Boström Andersson (Transaction Support Coordinator).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026